Titan Pharmaceuticals, Inc. (TTNP)

NASDAQ: TTNP · IEX Real-Time Price · USD

5.43

-0.11 (-1.99%)

At close: Jul 2, 2024, 4:00 PM

5.13

-0.30 (-5.52%)

After-hours: Jul 2, 2024, 4:44 PM EDT

Titan Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1995
Revenue	0.18	0.56	1.53	4.84	2.61	Upgrade
Revenue Growth (YoY)	-66.97%	-63.50%	-68.46%	85.72%	-60.64%	Upgrade
Cost of Revenue	0	0	0.2	0.47	0	Upgrade
Gross Profit	0.18	0.56	1.33	4.37	2.61	Upgrade
Selling, General & Admin	5.55	6.03	4.99	5.8	5.4	Upgrade
Research & Development	1.91	4.76	5.69	5.92	5.08	Upgrade
Operating Expenses	7.46	10.79	10.68	11.72	10.48	Upgrade
Operating Income	-7.28	-10.24	-9.35	-7.35	-7.88	Upgrade
Interest Expense / Income	0	0	0	0.77	0.97	Upgrade
Other Expense / Income	-1.71	-0.03	-0.58	10.12	7.62	Upgrade
Pretax Income	-5.57	-10.21	-8.78	-18.24	-16.46	Upgrade
Net Income	-5.57	-10.21	-8.78	-18.24	-16.46	Upgrade
Shares Outstanding (Basic)	1	1	0	0	0	Upgrade
Shares Outstanding (Diluted)	1	1	0	0	0	Upgrade
Shares Change	11.90%	38.13%	157.88%	392.56%	304.01%	Upgrade
EPS (Basic)	-7.41	-15.19	-18.00	-96.60	-429.80	Upgrade
EPS (Diluted)	-7.41	-15.19	-18.00	-96.60	-429.80	Upgrade
Free Cash Flow	-7.09	-8.18	-7.92	-17.74	-15.7	Upgrade
Free Cash Flow Per Share	-9.43	-12.18	-16.28	-94.05	-409.95	Upgrade
Gross Margin	100.00%	100.00%	86.96%	90.24%	100.00%	Upgrade
Operating Margin	-3954.89%	-1837.52%	-612.98%	-151.94%	-302.34%	Upgrade
Profit Margin	-3026.63%	-1832.32%	-575.10%	-377.06%	-631.79%	Upgrade
Free Cash Flow Margin	-3855.43%	-1469.12%	-519.13%	-366.74%	-602.73%	Upgrade
EBITDA	-5.46	-10.01	-8.56	-17.18	-15.25	Upgrade
EBITDA Margin	-2965.76%	-1797.13%	-560.62%	-355.13%	-585.30%	Upgrade
Depreciation & Amortization	0.11	0.2	0.22	0.29	0.24	Upgrade
EBIT	-5.57	-10.21	-8.78	-17.47	-15.49	Upgrade
EBIT Margin	-3026.63%	-1832.32%	-575.10%	-361.16%	-594.66%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).